Trials / Completed
CompletedNCT01700075
Physical and Chemical Study of Atherosclerosis Mechanisms
Comparative Physical and Chemical Study of the Mechanisms of Atherosclerosis With Development of Concept of Treatment and Prevention
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 97 (actual)
- Sponsor
- Nazarbayev University · Academic / Other
- Sex
- All
- Age
- 26 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
Study the mechanisms of atherosclerosis based on a comparative study of physical and chemical properties of lipid tissues at various localization with subsequent development of concept of treatment and prevention.
Detailed description
The chemical and physical properties of different lipids of body. The clinical part of the work is a prospective randomized comparative controlled clinical trial of patients with atherosclerotic diseases. Developed the concept of "limited biological resources" of the body based on the increase in the expenditure of energy reserves of the body, allowing a critical look at overweight. The role of overweight in the development of atheromatous fat was revealed. The positive results from the weight loss in patients with atherosclerotic disease were drawn. Developed the metabolic concept of atherosclerosis associated with evolutionary aging and conversion of lipids in hard atherosclerotic fat.
Conditions
- Myocardial Infarction
- Coronary Artery Diseases
- Diabetes Mellitus, Type 2
- Atherosclerosis of Femoral Artery
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Conventional treatment | Lipidlowering: "Atorvastatin" (Liprimar) - 40mg per day. Antihypertensive: "Diroton" (Lisinopril, Gedeon Richter Ltd) - 10mg twice per day and "Ditiazem" (calcium bloker from the benthodiazepines, Lannacher, Austria) - 90mg per day. Antihyperglycemic drugs: biguanides "Metformin" - 0.5 g two or tree times per day, or "Exenatide" - 5-10 µg per day. Anti-inflammatory: "TromboACC" (acetylsalicylate acid) up to 2 g per day and/or "Clopidogrel" (thienopyridine class antiplatelet agent) - 75mg per day. |
| DIETARY_SUPPLEMENT | Weight loss treatment | Weight loss treatment by administering a healthy very low-calorie, low-fat vegetables and salt diet and includes an adjustment and modify eating behavior and increased physical activity. |
Timeline
- Start date
- 2009-01-01
- Primary completion
- 2009-12-01
- Completion
- 2011-12-01
- First posted
- 2012-10-04
- Last updated
- 2012-10-04
Locations
1 site across 1 country: Kazakhstan
Source: ClinicalTrials.gov record NCT01700075. Inclusion in this directory is not an endorsement.